awmsg logo



darunavir (Prezista®)


Reference No. 2579

Publication date:
16/07/2015


Appraisal information

darunavir (Prezista®) 75 mg film-coated tablet
darunavir (Prezista®) 150 mg film-coated tablet
darunavir (Prezista®) 300 mg film-coated tablet
darunavir (Prezista®) 600 mg film-coated tablet
darunavir (Prezista®) 800 mg film-coated tablet
darunavir (Prezista®) 100 mg/ml oral suspension


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 13/05/2015
AWMSG meeting date: 17/06/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1815
Ministerial ratification: 15/07/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir (Prezista®) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of three years and at least 15 kg body weight.
Final Appraisal Recommendation (FAR)
Download
Clinical Expert (CE) Summary
Download